Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.
作者信息
Sarma Phulen, Prajapat Manisha, Avti Pramod, Kaur Hardeep, Kumar Subodh, Medhi Bikash
机构信息
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5. doi: 10.4103/ijp.IJP_119_20. Epub 2020 Mar 11.
Abstract
摘要
相似文献
1
Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.
Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5. doi: 10.4103/ijp.IJP_119_20. Epub 2020 Mar 11.
2
Sofosbuvir for COVID-19 infection: A potential candidate.
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
3
Is the type of diabetes treatment relevant to outcome of COVID-19?
J Diabetes. 2020 Jul;12(7):486-487. doi: 10.1111/1753-0407.13047.
4
Statins in coronavirus outbreak: It's time for experimental and clinical studies.
Pharmacol Res. 2020 Jun;156:104803. doi: 10.1016/j.phrs.2020.104803. Epub 2020 Apr 11.
5
Covid-19 treatment update: follow the scientific evidence.
J Thromb Thrombolysis. 2020 Jul;50(1):43-53. doi: 10.1007/s11239-020-02120-9.
6
COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.
Open Heart. 2020 Jun;7(1). doi: 10.1136/openhrt-2020-001302.
7
Coronavirus disease 2019 infection and the cardiovascular system.
J Cardiovasc Med (Hagerstown). 2020 Jun;21(6):403-405. doi: 10.2459/JCM.0000000000000980.
8
Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients.
Indian J Pharmacol. 2020 May-Jun;52(3):229-231. doi: 10.4103/ijp.IJP_595_20. Epub 2020 Aug 4.
9
Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.
Prog Cardiovasc Dis. 2020 May-Jun;63(3):383-385. doi: 10.1016/j.pcad.2020.02.007. Epub 2020 Feb 12.
10
Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.
Thromb Res. 2020 Aug;192:27-28. doi: 10.1016/j.thromres.2020.05.015. Epub 2020 May 14.
引用本文的文献
1
Safety of Hydroxychloroquine for COVID-19 Prophylaxis in Healthcare Workers: A Cross-Sectional Study.
Cureus. 2025 Feb 25;17(2):e79660. doi: 10.7759/cureus.79660. eCollection 2025 Feb.
2
Stability, homogeneity and measurement uncertainty estimation of PVP-I solutions for the application on oro and nasopharynx against SARS-CoV-2.
Sci Rep. 2024 Mar 27;14(1):7268. doi: 10.1038/s41598-024-52346-3.
3
Insight into the mechanisms of coronaviruses evading host innate immunity.
Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166671. doi: 10.1016/j.bbadis.2023.166671. Epub 2023 Feb 27.
4
In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease.
Molecules. 2022 Sep 27;27(19):6374. doi: 10.3390/molecules27196374.
5
Effectiveness of Plasmapheresis Treatment in the Treatment of Patients with COVID-19 Disease.
Med J Islam Repub Iran. 2022 Jul 25;36:83. doi: 10.47176/mjiri.36.83. eCollection 2022.
6
Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity.
Mol Biomed. 2022 Jul 15;3(1):21. doi: 10.1186/s43556-022-00078-z.
7
Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 spike interaction with hACE2.
Cell Rep Methods. 2022 Jul 18;2(7):100252. doi: 10.1016/j.crmeth.2022.100252. Epub 2022 Jun 20.
8
COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis.
Indian J Pharmacol. 2021 Nov-Dec;53(6):499-510. doi: 10.4103/ijp.ijp_839_21.
9
SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review.
Int J Biol Macromol. 2021 Dec 15;193(Pt B):1249-1273. doi: 10.1016/j.ijbiomac.2021.10.172. Epub 2021 Oct 28.
10
An Examination of the Factors Affecting Community Pharmacists' Knowledge, Attitudes, and Impressions About the COVID-19 Pandemic.
Turk J Pharm Sci. 2021 Oct 28;18(5):530-540. doi: 10.4274/tjps.galenos.2020.01212.
本文引用的文献
1
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.
2
Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province.
Chin Med J (Engl). 2020 May 5;133(9):1025-1031. doi: 10.1097/CM9.0000000000000744.
3
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
4
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
Biosci Trends. 2020 Mar 16;14(1):64-68. doi: 10.5582/bst.2020.01030. Epub 2020 Feb 9.
5
Reducing mortality from 2019-nCoV: host-directed therapies should be an option.
Lancet. 2020 Feb 22;395(10224):e35-e36. doi: 10.1016/S0140-6736(20)30305-6. Epub 2020 Feb 5.
6
Clinical Features and Treatment of 2019-nCov Pneumonia Patients in Wuhan: Report of A Couple Cases.
Virol Sin. 2020 Jun;35(3):330-336. doi: 10.1007/s12250-020-00203-8. Epub 2020 Feb 7.
7
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
8
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
9
2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution.
Swiss Med Wkly. 2020 Feb 7;150:w20203. doi: 10.4414/smw.2020.20203. eCollection 2020 Jan 27.
10
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).
Mil Med Res. 2020 Feb 6;7(1):4. doi: 10.1186/s40779-020-0233-6.
Zotero 插件